Great, it's nice to have alternative drugs but mice and pigs ain't humans....
They lost me when predicting no muscle loss in humans based on a SHORT mouse study...
Either these researchers don't know how the human body actually works(doubtful)or are trying to be misleading... (Eh clickbait culture...)
Obese humans lose muscle as they lose weight because as the body becomes leaner it needs less muscle to move around and people are still lazy POS so they don't increase activity much after leaning out ,mice on the other hand do move around more so might have a chance to keep the muscle until the deficit is so high that it does not matter, but the study was not long enough....
No way this magic molecule is preventing muscle loss without affecting the regulating and limiting systems of the body and having all sorts of side effects on heart etc....
It would be the holy grail of fatloss if it was true but I wouldn't hold my breath..
Imagine if you were taking this and AAS losing fat and gaining even more muscle
I'm not exactly sure where in the article you're extrapolating these definitive claims from; nowhere in the article does it mention the researchers making bold and conclusive statements regarding this molecule. This is essentially preliminary research investigating a molecule that may have potential for use in future weight-loss medicine.
This type of probing research always begins with trials using animal subjects to assess the efficacy and (more importantly) safety of a proposed drug before moving on to clinical trials using human subjects. That's rudimentary pharmacology research ethics; no ethics panel would ever greenlight a study using human subjects before the researchers have demonstrated a certain level of safety with animal subjects (typically poor, little rodents).
To quote the senior author of the research (and this is directly from the article):
"Nothing we've tested before has compared to semaglutide's ability to decrease appetite and body weight.
We are very eager to learn if it is safe and effective in humans." (My emphasis with the bold/italic)
As you can see, the researchers are well aware that there is much more research to be done on this molecule before they can assert anything substantial about its practical implementation in clinical medicine. Nonetheless, what they have found so far is very interesting and promising, specifically because unlike the current wave of GLP/GIP/glucagon agonist medications, this molecule is not an incretin, so this could lead to the discovery of an entirely new physiological mechanism by which the body's appetite could be manipulated in favor of reducing calorie intake (i.e., weight/fat loss). Or, it could fail to produce meaningful results and fizzle-out into obscurity; but even if this molecule itself does not turn out to be what they had hoped, further research could indirectly lead to the discovery of something else that does end up being efficacious. Science tends to be unpredictable like that; a lot of breakthroughs were kind of just accidentally stumbled onto, in many fields.
Oh, and as an aside, I forgot to post the link to the actual study, not just the article (even though the link is also in the article).
Computational drug discovery is used to identify a 12-mer peptide derived from BRINP2 with potent anti-obesity effects that are independent of leptin, glucagon-like peptide 1 receptor and melanocortin 4 receptor.
www.nature.com
